Structured Review

BioreclamationIVT pbmcs
Assay utility in <t>CLL</t> and DLBCL patient samples: ( A ) <t>PBMCs,</t> ( B ) lymph nodes, and ( C ) bone marrow. ( A ) The concentration of total BTK in PBMCs from nine patients with CLL ranged from 33 to 174 ng/mL. The average total BTK expression in PBMCs from four healthy volunteers (HV, gray bar) was 30 ng/mL. Data represent the average and standard error of quadruplicate samples from each subject or from four healthy donors tested in quadruplicate. ( B ) The TR-FRET assay detected robust levels of free (light blue bars) and total (dark blue bars) BTK in lymph node (LN) tissue lysates from two patients with DLBCL. Data represent the average and standard error from samples tested in triplicate. ( C ) Matched BMMCs and PBMCs from two patients with CLL were treated by spiking 110, 8, and 0.1 nM tirabrutinib with a final DMSO concentration of 0.1%. The TR-FRET assay showed dose-dependent BTK binding after ex vivo treatment with tirabrutinib. BTK occupancy reached nearly 100% at a dose of 110 nM tirabrutinib. Data represent the average and standard error from triplicate samples.
Pbmcs, supplied by BioreclamationIVT, used in various techniques. Bioz Stars score: 92/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pbmcs/product/BioreclamationIVT
Average 92 stars, based on 3 article reviews
Price from $9.99 to $1999.99
pbmcs - by Bioz Stars, 2020-09
92/100 stars

Images

1) Product Images from "Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement"

Article Title: Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement

Journal: Slas Discovery

doi: 10.1177/2472555218786165

Assay utility in CLL and DLBCL patient samples: ( A ) PBMCs, ( B ) lymph nodes, and ( C ) bone marrow. ( A ) The concentration of total BTK in PBMCs from nine patients with CLL ranged from 33 to 174 ng/mL. The average total BTK expression in PBMCs from four healthy volunteers (HV, gray bar) was 30 ng/mL. Data represent the average and standard error of quadruplicate samples from each subject or from four healthy donors tested in quadruplicate. ( B ) The TR-FRET assay detected robust levels of free (light blue bars) and total (dark blue bars) BTK in lymph node (LN) tissue lysates from two patients with DLBCL. Data represent the average and standard error from samples tested in triplicate. ( C ) Matched BMMCs and PBMCs from two patients with CLL were treated by spiking 110, 8, and 0.1 nM tirabrutinib with a final DMSO concentration of 0.1%. The TR-FRET assay showed dose-dependent BTK binding after ex vivo treatment with tirabrutinib. BTK occupancy reached nearly 100% at a dose of 110 nM tirabrutinib. Data represent the average and standard error from triplicate samples.
Figure Legend Snippet: Assay utility in CLL and DLBCL patient samples: ( A ) PBMCs, ( B ) lymph nodes, and ( C ) bone marrow. ( A ) The concentration of total BTK in PBMCs from nine patients with CLL ranged from 33 to 174 ng/mL. The average total BTK expression in PBMCs from four healthy volunteers (HV, gray bar) was 30 ng/mL. Data represent the average and standard error of quadruplicate samples from each subject or from four healthy donors tested in quadruplicate. ( B ) The TR-FRET assay detected robust levels of free (light blue bars) and total (dark blue bars) BTK in lymph node (LN) tissue lysates from two patients with DLBCL. Data represent the average and standard error from samples tested in triplicate. ( C ) Matched BMMCs and PBMCs from two patients with CLL were treated by spiking 110, 8, and 0.1 nM tirabrutinib with a final DMSO concentration of 0.1%. The TR-FRET assay showed dose-dependent BTK binding after ex vivo treatment with tirabrutinib. BTK occupancy reached nearly 100% at a dose of 110 nM tirabrutinib. Data represent the average and standard error from triplicate samples.

Techniques Used: Concentration Assay, Expressing, Binding Assay, Ex Vivo

2) Product Images from "Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement"

Article Title: Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement

Journal: Slas Discovery

doi: 10.1177/2472555218786165

Assay utility in CLL and DLBCL patient samples: ( A ) PBMCs, ( B ) lymph nodes, and ( C ) bone marrow. ( A ) The concentration of total BTK in PBMCs from nine patients with CLL ranged from 33 to 174 ng/mL. The average total BTK expression in PBMCs from four healthy volunteers (HV, gray bar) was 30 ng/mL. Data represent the average and standard error of quadruplicate samples from each subject or from four healthy donors tested in quadruplicate. ( B ) The TR-FRET assay detected robust levels of free (light blue bars) and total (dark blue bars) BTK in lymph node (LN) tissue lysates from two patients with DLBCL. Data represent the average and standard error from samples tested in triplicate. ( C ) Matched BMMCs and PBMCs from two patients with CLL were treated by spiking 110, 8, and 0.1 nM tirabrutinib with a final DMSO concentration of 0.1%. The TR-FRET assay showed dose-dependent BTK binding after ex vivo treatment with tirabrutinib. BTK occupancy reached nearly 100% at a dose of 110 nM tirabrutinib. Data represent the average and standard error from triplicate samples.
Figure Legend Snippet: Assay utility in CLL and DLBCL patient samples: ( A ) PBMCs, ( B ) lymph nodes, and ( C ) bone marrow. ( A ) The concentration of total BTK in PBMCs from nine patients with CLL ranged from 33 to 174 ng/mL. The average total BTK expression in PBMCs from four healthy volunteers (HV, gray bar) was 30 ng/mL. Data represent the average and standard error of quadruplicate samples from each subject or from four healthy donors tested in quadruplicate. ( B ) The TR-FRET assay detected robust levels of free (light blue bars) and total (dark blue bars) BTK in lymph node (LN) tissue lysates from two patients with DLBCL. Data represent the average and standard error from samples tested in triplicate. ( C ) Matched BMMCs and PBMCs from two patients with CLL were treated by spiking 110, 8, and 0.1 nM tirabrutinib with a final DMSO concentration of 0.1%. The TR-FRET assay showed dose-dependent BTK binding after ex vivo treatment with tirabrutinib. BTK occupancy reached nearly 100% at a dose of 110 nM tirabrutinib. Data represent the average and standard error from triplicate samples.

Techniques Used: Concentration Assay, Expressing, Binding Assay, Ex Vivo

3) Product Images from "Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement"

Article Title: Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement

Journal: Slas Discovery

doi: 10.1177/2472555218786165

Assay utility in CLL and DLBCL patient samples: ( A ) PBMCs, ( B ) lymph nodes, and ( C ) bone marrow. ( A ) The concentration of total BTK in PBMCs from nine patients with CLL ranged from 33 to 174 ng/mL. The average total BTK expression in PBMCs from four healthy volunteers (HV, gray bar) was 30 ng/mL. Data represent the average and standard error of quadruplicate samples from each subject or from four healthy donors tested in quadruplicate. ( B ) The TR-FRET assay detected robust levels of free (light blue bars) and total (dark blue bars) BTK in lymph node (LN) tissue lysates from two patients with DLBCL. Data represent the average and standard error from samples tested in triplicate. ( C ) Matched BMMCs and PBMCs from two patients with CLL were treated by spiking 110, 8, and 0.1 nM tirabrutinib with a final DMSO concentration of 0.1%. The TR-FRET assay showed dose-dependent BTK binding after ex vivo treatment with tirabrutinib. BTK occupancy reached nearly 100% at a dose of 110 nM tirabrutinib. Data represent the average and standard error from triplicate samples.
Figure Legend Snippet: Assay utility in CLL and DLBCL patient samples: ( A ) PBMCs, ( B ) lymph nodes, and ( C ) bone marrow. ( A ) The concentration of total BTK in PBMCs from nine patients with CLL ranged from 33 to 174 ng/mL. The average total BTK expression in PBMCs from four healthy volunteers (HV, gray bar) was 30 ng/mL. Data represent the average and standard error of quadruplicate samples from each subject or from four healthy donors tested in quadruplicate. ( B ) The TR-FRET assay detected robust levels of free (light blue bars) and total (dark blue bars) BTK in lymph node (LN) tissue lysates from two patients with DLBCL. Data represent the average and standard error from samples tested in triplicate. ( C ) Matched BMMCs and PBMCs from two patients with CLL were treated by spiking 110, 8, and 0.1 nM tirabrutinib with a final DMSO concentration of 0.1%. The TR-FRET assay showed dose-dependent BTK binding after ex vivo treatment with tirabrutinib. BTK occupancy reached nearly 100% at a dose of 110 nM tirabrutinib. Data represent the average and standard error from triplicate samples.

Techniques Used: Concentration Assay, Expressing, Binding Assay, Ex Vivo

Related Articles

Isolation:

Article Title: Positive regulation of prostate cancer cell growth by lipid droplet forming and processing enzymes DGAT1 and ABHD5
Article Snippet: .. PBMCs were isolated from fresh volunteer blood samples or were purchased along with plasma from Bioreclamation IVT, USA. .. PBMCs were growth in X-vivo15 media with or without phenol red (for MTS assay) from Lonza (Allandale, NJ).

Gradient Centrifugation:

Article Title: Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement
Article Snippet: .. Concurrently with the Fel d 1 and antibody pre-incubation, PBMCs (BioreclamationIVT) were purified from fresh whole blood from allergic donors by Ficoll density gradient centrifugation. .. The purified PBMCs were washed, resuspended in X-VIVO 15 media (Lonza), and plated in duplicate columns in a v-bottom, polypropylene, 96-well plate (approximately 5 × 105 cells/well).

other:

Article Title: Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement
Article Snippet: PBMCs and Bone Marrow Cells Cryopreserved PBMCs from CLL patients were purchased from BioreclamationIVT (Chestertown, MD) and lysates were prepared for healthy volunteer PBMCs as described above.

Article Title: Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement
Article Snippet: Cryopreserved PBMCs from CLL patients were purchased from BioreclamationIVT (Chestertown, MD) and lysates were prepared for healthy volunteer PBMCs as described above.

Expressing:

Article Title: Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus
Article Snippet: .. PBMC samples for CD38 expression analysis from patients with SLE and RA and from healthy donors were acquired from Bioreclamation (Westbury, NY, USA) and Precision for Medicine (Frederick, MD, USA). ..

Purification:

Article Title: Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement
Article Snippet: .. Concurrently with the Fel d 1 and antibody pre-incubation, PBMCs (BioreclamationIVT) were purified from fresh whole blood from allergic donors by Ficoll density gradient centrifugation. .. The purified PBMCs were washed, resuspended in X-VIVO 15 media (Lonza), and plated in duplicate columns in a v-bottom, polypropylene, 96-well plate (approximately 5 × 105 cells/well).

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 89
    BioreclamationIVT autologous pbmc
    Priming an adaptive T cell immune response. CTL were primed from <t>PBMC</t> <t>cocultured</t> with autologous DC that had been loaded with either Mel888 (control) or Mel888 treated with Mv at an MOI of 0.1 (0.1). A ; Degranulation of CTL following coculture with either Mel888, SkOV or an equal volume of media free of target cells. B ; Intracellular IFNγ within CTL primed from PBMC following coculture with Mel888, SkOV or media control. C ; Cr-51 release from Mel888 following coculture with CTL; no significant release of Cr51 was detected from irrelevant SkOV targets. Data shown are from one donor, representative of experiments in 12 donors, in 9 of which a specific anti-melanoma response was elicited.
    Autologous Pbmc, supplied by BioreclamationIVT, used in various techniques. Bioz Stars score: 89/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/autologous pbmc/product/BioreclamationIVT
    Average 89 stars, based on 4 article reviews
    Price from $9.99 to $1999.99
    autologous pbmc - by Bioz Stars, 2020-09
    89/100 stars
      Buy from Supplier

    88
    BioreclamationIVT nucleotide kinases pbmc
    Targeted <t>siRNA</t> knockdown of nucleotide kinases in <t>PBMC,</t> colorectal tissue, and vaginal tissue and the resulting impact on TFV-MP and TFV-DP intracellular formation. PBMC, colorectal tissue, and vaginal tissue were electroporated with 500 nM non-targeting siRNA or siRNA targeting AK2, GUK1, PKM, PKLR, and CKM and incubated for 24 h or 48 h for tissue or PBMC, respectively. Representative immunoblots demonstrate decreased nucleotide kinase expression with each targeted siRNA treatment relative to the non-targeting siRNA control. siRNA treated (a) PBMC, (b) colorectal tissue, and (c) vaginal tissue were incubated with 10 μM TFV for 12 h (n = 3 per treatment). Intracellular anabolites were extracted from which TFV-MP and TFV-DP were detected using uHPLC–MS/MS as depicted in the corresponding bar graphs showing mean ± standard deviation for each treatment. Statistical analyses were performed using a two-tailed unpaired t test to compare relative levels of anabolite production between non-targeted and targeted siRNA conditions; ** = p ≤ 0.01; *** = p ≤ 0.001.
    Nucleotide Kinases Pbmc, supplied by BioreclamationIVT, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nucleotide kinases pbmc/product/BioreclamationIVT
    Average 88 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    nucleotide kinases pbmc - by Bioz Stars, 2020-09
    88/100 stars
      Buy from Supplier

    Image Search Results


    Priming an adaptive T cell immune response. CTL were primed from PBMC cocultured with autologous DC that had been loaded with either Mel888 (control) or Mel888 treated with Mv at an MOI of 0.1 (0.1). A ; Degranulation of CTL following coculture with either Mel888, SkOV or an equal volume of media free of target cells. B ; Intracellular IFNγ within CTL primed from PBMC following coculture with Mel888, SkOV or media control. C ; Cr-51 release from Mel888 following coculture with CTL; no significant release of Cr51 was detected from irrelevant SkOV targets. Data shown are from one donor, representative of experiments in 12 donors, in 9 of which a specific anti-melanoma response was elicited.

    Journal: Gene therapy

    Article Title: Measles virus causes immunogenic cell death in human melanoma

    doi: 10.1038/gt.2011.205

    Figure Lengend Snippet: Priming an adaptive T cell immune response. CTL were primed from PBMC cocultured with autologous DC that had been loaded with either Mel888 (control) or Mel888 treated with Mv at an MOI of 0.1 (0.1). A ; Degranulation of CTL following coculture with either Mel888, SkOV or an equal volume of media free of target cells. B ; Intracellular IFNγ within CTL primed from PBMC following coculture with Mel888, SkOV or media control. C ; Cr-51 release from Mel888 following coculture with CTL; no significant release of Cr51 was detected from irrelevant SkOV targets. Data shown are from one donor, representative of experiments in 12 donors, in 9 of which a specific anti-melanoma response was elicited.

    Article Snippet: After 24 hours non-adherent DC were harvested then cocultured with autologous PBMC at ratios varying from 1:15 to 1:45 in CTL media (RPMI supplemented with 7.5% (v/v) human AB serum (Sera Laboratories Int., Hayward’s Heath, UK ), 1% (v/v) L-glutamine, 1% v/v sodium pyruvate (Invitrogen), 1% (v/v) non-essential amino acids, 1% (v/v) HEPES (Invitrogen), 20μM β-mercaptoethanol (Sigma)) and 5ng/ml IL-7 (R & D Systems).

    Techniques: CTL Assay

    Assay utility in CLL and DLBCL patient samples: ( A ) PBMCs, ( B ) lymph nodes, and ( C ) bone marrow. ( A ) The concentration of total BTK in PBMCs from nine patients with CLL ranged from 33 to 174 ng/mL. The average total BTK expression in PBMCs from four healthy volunteers (HV, gray bar) was 30 ng/mL. Data represent the average and standard error of quadruplicate samples from each subject or from four healthy donors tested in quadruplicate. ( B ) The TR-FRET assay detected robust levels of free (light blue bars) and total (dark blue bars) BTK in lymph node (LN) tissue lysates from two patients with DLBCL. Data represent the average and standard error from samples tested in triplicate. ( C ) Matched BMMCs and PBMCs from two patients with CLL were treated by spiking 110, 8, and 0.1 nM tirabrutinib with a final DMSO concentration of 0.1%. The TR-FRET assay showed dose-dependent BTK binding after ex vivo treatment with tirabrutinib. BTK occupancy reached nearly 100% at a dose of 110 nM tirabrutinib. Data represent the average and standard error from triplicate samples.

    Journal: Slas Discovery

    Article Title: Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement

    doi: 10.1177/2472555218786165

    Figure Lengend Snippet: Assay utility in CLL and DLBCL patient samples: ( A ) PBMCs, ( B ) lymph nodes, and ( C ) bone marrow. ( A ) The concentration of total BTK in PBMCs from nine patients with CLL ranged from 33 to 174 ng/mL. The average total BTK expression in PBMCs from four healthy volunteers (HV, gray bar) was 30 ng/mL. Data represent the average and standard error of quadruplicate samples from each subject or from four healthy donors tested in quadruplicate. ( B ) The TR-FRET assay detected robust levels of free (light blue bars) and total (dark blue bars) BTK in lymph node (LN) tissue lysates from two patients with DLBCL. Data represent the average and standard error from samples tested in triplicate. ( C ) Matched BMMCs and PBMCs from two patients with CLL were treated by spiking 110, 8, and 0.1 nM tirabrutinib with a final DMSO concentration of 0.1%. The TR-FRET assay showed dose-dependent BTK binding after ex vivo treatment with tirabrutinib. BTK occupancy reached nearly 100% at a dose of 110 nM tirabrutinib. Data represent the average and standard error from triplicate samples.

    Article Snippet: PBMCs and Bone Marrow Cells Cryopreserved PBMCs from CLL patients were purchased from BioreclamationIVT (Chestertown, MD) and lysates were prepared for healthy volunteer PBMCs as described above.

    Techniques: Concentration Assay, Expressing, Binding Assay, Ex Vivo

    Assay utility in CLL and DLBCL patient samples: ( A ) PBMCs, ( B ) lymph nodes, and ( C ) bone marrow. ( A ) The concentration of total BTK in PBMCs from nine patients with CLL ranged from 33 to 174 ng/mL. The average total BTK expression in PBMCs from four healthy volunteers (HV, gray bar) was 30 ng/mL. Data represent the average and standard error of quadruplicate samples from each subject or from four healthy donors tested in quadruplicate. ( B ) The TR-FRET assay detected robust levels of free (light blue bars) and total (dark blue bars) BTK in lymph node (LN) tissue lysates from two patients with DLBCL. Data represent the average and standard error from samples tested in triplicate. ( C ) Matched BMMCs and PBMCs from two patients with CLL were treated by spiking 110, 8, and 0.1 nM tirabrutinib with a final DMSO concentration of 0.1%. The TR-FRET assay showed dose-dependent BTK binding after ex vivo treatment with tirabrutinib. BTK occupancy reached nearly 100% at a dose of 110 nM tirabrutinib. Data represent the average and standard error from triplicate samples.

    Journal: Slas Discovery

    Article Title: Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement

    doi: 10.1177/2472555218786165

    Figure Lengend Snippet: Assay utility in CLL and DLBCL patient samples: ( A ) PBMCs, ( B ) lymph nodes, and ( C ) bone marrow. ( A ) The concentration of total BTK in PBMCs from nine patients with CLL ranged from 33 to 174 ng/mL. The average total BTK expression in PBMCs from four healthy volunteers (HV, gray bar) was 30 ng/mL. Data represent the average and standard error of quadruplicate samples from each subject or from four healthy donors tested in quadruplicate. ( B ) The TR-FRET assay detected robust levels of free (light blue bars) and total (dark blue bars) BTK in lymph node (LN) tissue lysates from two patients with DLBCL. Data represent the average and standard error from samples tested in triplicate. ( C ) Matched BMMCs and PBMCs from two patients with CLL were treated by spiking 110, 8, and 0.1 nM tirabrutinib with a final DMSO concentration of 0.1%. The TR-FRET assay showed dose-dependent BTK binding after ex vivo treatment with tirabrutinib. BTK occupancy reached nearly 100% at a dose of 110 nM tirabrutinib. Data represent the average and standard error from triplicate samples.

    Article Snippet: Cryopreserved PBMCs from CLL patients were purchased from BioreclamationIVT (Chestertown, MD) and lysates were prepared for healthy volunteer PBMCs as described above.

    Techniques: Concentration Assay, Expressing, Binding Assay, Ex Vivo

    Targeted siRNA knockdown of nucleotide kinases in PBMC, colorectal tissue, and vaginal tissue and the resulting impact on TFV-MP and TFV-DP intracellular formation. PBMC, colorectal tissue, and vaginal tissue were electroporated with 500 nM non-targeting siRNA or siRNA targeting AK2, GUK1, PKM, PKLR, and CKM and incubated for 24 h or 48 h for tissue or PBMC, respectively. Representative immunoblots demonstrate decreased nucleotide kinase expression with each targeted siRNA treatment relative to the non-targeting siRNA control. siRNA treated (a) PBMC, (b) colorectal tissue, and (c) vaginal tissue were incubated with 10 μM TFV for 12 h (n = 3 per treatment). Intracellular anabolites were extracted from which TFV-MP and TFV-DP were detected using uHPLC–MS/MS as depicted in the corresponding bar graphs showing mean ± standard deviation for each treatment. Statistical analyses were performed using a two-tailed unpaired t test to compare relative levels of anabolite production between non-targeted and targeted siRNA conditions; ** = p ≤ 0.01; *** = p ≤ 0.001.

    Journal: EBioMedicine

    Article Title: Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner

    doi: 10.1016/j.ebiom.2015.07.008

    Figure Lengend Snippet: Targeted siRNA knockdown of nucleotide kinases in PBMC, colorectal tissue, and vaginal tissue and the resulting impact on TFV-MP and TFV-DP intracellular formation. PBMC, colorectal tissue, and vaginal tissue were electroporated with 500 nM non-targeting siRNA or siRNA targeting AK2, GUK1, PKM, PKLR, and CKM and incubated for 24 h or 48 h for tissue or PBMC, respectively. Representative immunoblots demonstrate decreased nucleotide kinase expression with each targeted siRNA treatment relative to the non-targeting siRNA control. siRNA treated (a) PBMC, (b) colorectal tissue, and (c) vaginal tissue were incubated with 10 μM TFV for 12 h (n = 3 per treatment). Intracellular anabolites were extracted from which TFV-MP and TFV-DP were detected using uHPLC–MS/MS as depicted in the corresponding bar graphs showing mean ± standard deviation for each treatment. Statistical analyses were performed using a two-tailed unpaired t test to compare relative levels of anabolite production between non-targeted and targeted siRNA conditions; ** = p ≤ 0.01; *** = p ≤ 0.001.

    Article Snippet: 2.1 siRNA Knockdown of Nucleotide Kinases PBMC were obtained from Bioreclamation (Westbury, NY), and fresh vaginal and colorectal biopsies were obtained from the Johns Hopkins University School of Medicine Tissue Bank (Baltimore, MD).

    Techniques: Incubation, Western Blot, Expressing, Mass Spectrometry, Standard Deviation, Two Tailed Test